Craft
  • Home
  •  / Owlstone Medical
Owlstone Medical

Owlstone Medical

Revenue

£2.6 M

FY, 2018

Total Funding

$66.5 M

Owlstone Medical Summary

Company summary

Overview
Owlstone Medical provides medical products and services. The Company offers a Breath Biopsy platform, a diagnostic modality capable of detecting disease biomarkers in breath. It also develops tests for lung and colorectal cancer, as well as for asthma stratification by therapeutic response. Owlstone Medical offers its products and services to academic, clinical and pharmaceutical partners who want to develop breath based biomarkers for their own applications.
Type
Private
Founded
2004
HQ
Milton, GB | view all locations
Website
http://www.owlstonemedical.com/
Cybersecurity rating
Sectors

Key people

  • Billy Boyle

    Billy Boyle, Co-Founder, Chief Executive Officer and Director

  • David Ruiz-Alonso

    David Ruiz-Alonso, Co-Founder and Chief Operating Officer, Director

  • Kevin Chalmers

    Kevin Chalmers, Vice President Engineering and Operations

  • Huw Davies

    Huw Davies, Vice President of Global Sales

Operating MetricsView all

Patients Recruited in Clinical Trials to Date

1.8K
203.3%

FY, 2017

Diagnostic Outcomes to Date

1.5K
597.2%

FY, 2017

Patients Recruited in Clinical Trials, InTERCEPT

1.4K

Mar, 2019

LocationsView all

5 locations detected

  • Milton, England HQ

    United Kingdom

    183 Cambridge Science Park Milton Rd

  • Westport, CT

    United States

    suite #202, 19 Ludlow Road, Westport

  • NC

    United States

    600 Park Offices Dr #140, Research Triangle

  • London, England

    United Kingdom

    Richmond Rd

  • Milton, England

    United Kingdom

    162 Cambridge Science Park Milton Rd

Owlstone Medical Financials

Summary financials

Revenue (FY, 2018)
£2.6M
Gross profit (FY, 2018)
£1.8M
Net income (FY, 2018)
(£7.9M)
Cash (FY, 2018)
£36.6M
EBIT (FY, 2018)
(£9.5M)

News

Footer menu